ACTIVITIES OF PROXIMAL TUBULE ENZYMES IN URINE OF PATIENTS TREATED WITH GENTAMICIN

Similar documents
Effects of Fasting on Temporal Variations in Nephrotoxicity of Gentamicin in Rats

Effectiveness and Toxicity of Gentamicin in an Experimental Model of Pyelonephritis: Effect of the Time of Administration

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008

European Public MRL assessment report (EPMAR)

GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS

Patients. Excludes paediatrics, neonates.

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

Aspects of the Chronic Toxicity of Gentamicin Sulfate in Cats

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Protein Synthesis Inhibitors

Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Ylva Sjöström 1) and Anna Lennquist 2)

Pharmacological Evaluation of Amikacin in Neonates

ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS

Research update - medicines for koalas

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

Bacterial infections in the urinary tract

Le infezioni di cute e tessuti molli

Introduction to Pharmacokinetics and Pharmacodynamics

Other Beta - lactam Antibiotics

Approach to pediatric Antibiotics

Appropriate antimicrobial therapy in HAP: What does this mean?

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

Management of Native Valve

Original Research Article

Acute Pyelonephritis POAC Guideline

Persistent in Kidneys

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and

Speciality: Therapeutics

Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization

IJBCP International Journal of Basic & Clinical Pharmacology


Dr Eleri Davies. Consultant Microbiologist and Infection Control Doctor, Public Health Wales NHS Trust

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

ANTIMICROBIAL STEWARDSHIP: THE ROLE OF THE CLINICIAN SAM GUREVITZ PHARM D, CGP BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCES

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

Assessing antihypertensive adherence with therapeutic drug monitoring Erika SW JONES, Maia LESOSKY, Marc BLOCKMAN, Sandra CASTEL, Eric H DECLOEDT,

UTI Dr S Mathijs Department of Pharmacology

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

MIACIN HIKMA PHARMACEUTICALS

Curricular Components for Infectious Diseases EPA

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

Super Bugs and Wonder Drugs: Protecting the One While Respecting the Many

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012

Author - Dr. Josie Traub-Dargatz

ANTIBIOTIC USE GUIDELINES FOR URINARY TRACT AND RESPIRATORY DISEASE

One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates (Review)

Comparative Low-Dose Nephrotoxicities of Gentamicin, Tobramycin, and Amikacin

Original Article Levofloxacin and Gentamicin Induced Nephrotoxicity Pak Armed Forces Med J 2015; 65(4): ORIGINAL ARTICLES

Antibiotic Updates: Part II

Health Products Regulatory Authority

SEASONAL TRENDS IN ANTIBIOTIC USAGE AMONG PAEDIATRIC OUTPATIENTS

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

RENAL CLEARANCE OF CARPROFEN IN THE ISOLATED PERFUSED RAT KIDNEY

1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

The CARI Guidelines Caring for Australians with Renal Impairment. 10. Treatment of peritoneal dialysis associated fungal peritonitis

Comparison of the Nephrotoxicity of Netilmicin and

folate-derived cofactors purines pyrimidines Sulfonamides sulfa drugs Trimethoprim infecting bacterium to perform DNA synthesis cotrimoxazole

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES

Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle

Study of First Line Antibiotics in Lower Respiratory Tract Infections in Children

GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

SUMMARY OF PRODUCT CHARACTERISTICS

Dose-Dependent Amelioration of Gentamicin-Induced Nephrotoxicity in Adult Swiss Albino Rats by Vitamin B-complex - A Preliminary Study

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance

Summary of Product Characteristics

A Study on Urinary Tract Infection Pathogen Profile and Their In Vitro Susceptibility to Antimicrobial Agents

ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE

Introduction to Antimicrobial Therapy

Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran

Assessment of gentamiciminduced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium

European public MRL assessment report (EPMAR)

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Amoxicillin Introduction: Mechanism of action: Pharmacology: Indications: Dosage: 12 Weeks ( 3 Months):

Chapter 51. Clinical Use of Antimicrobial Agents

Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections

Pharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles

ENVIRACOR J-5 aids in the control of clinical signs associated with Escherichia coli (E. coli) mastitis

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Acinetobacter species-associated infections and their antibiotic susceptibility profiles in Malaysia.

Antimicrobial therapy in critical care

ANTIMICROBIAL DOSING GUIDE 2013

DRAFT DRAFT. Paediatric Antibiotic Prescribing Guideline. May

Therios 300 mg and 750 mg Palatable Tablets for Dogs

Sepsis is the leading cause of morbidity and mortality in

Standing Orders for the Treatment of Outpatient Peritonitis

Transcription:

JMB 2007; 26 (1) DOI: 10.2478/v10011-007-0009-5 UDK 577.1 : 61 ISSN 1452-8258 JMB 26: 46 50, 2007 Original paper Originalni nau~ni rad ACTIVITIES OF PROXIMAL TUBULE ENZYMES IN URINE OF PATIENTS TREATED WITH GENTAMICIN AKTIVNOST ENZIMA PROKSIMALNIH TUBULA U URINU PACIJENATA TRETIRANIH GENTAMICINOM Biljana Davidovi} 1, Jelica Predojevi}-Samard`i} 2, Sne`ana Uletilovi} 1, Dragana Mal~i} 1, @ivko Sani~anin 1 1Faculty of Medicine, University of Banjaluka, Republic of Srpska, Bosnia and Herzegovina 2Pediatric Clinic, Clinical Centre of Banjaluka, Republic of Srpska, Bosnia and Herzegovina Summary: The activities of the enzymes dominantly localized within the proximal tubules, such as alanine aminopeptidase (AAP), gamma-glutamyl transferase (GGT) and N- acetyl-beta-d-glucosaminidase (NAG), were measured in 12-h urine samples of patients suffering from Gram-negative infections and i.v. treated with gentamicin with the aim of determining the nephrotoxicity of this aminoglycoside antibiotic. The examined groups consisted of 3 10 years old children of both sexes, gentamicin-treated, and the control group, each including 30 patients. Urine samples were collected and analyzed five days before the gentamicin application and during the following 10 days of gentamicin treatment (a single i.v. injection per day in the dose of 2.5 mg/kg b.w.). Significant differences in the AAP and GGT activities expressed in U/mmol creatinine were observed between the gentamicin-treated group and the controls already on day 2 (p < 0.05) of the treatment, as well as in the activity of NAG on day 8 (p < 0.01) of the therapy. From these results it can be concluded that even standard gentamicin doses expressed nephrotoxic effects. Statistically significantly increased AAP and GGT activities in the gentamicin-treated group of children recorded already on the 2nd day of treatment demonstrate that these two enzymes represent extremely sensitive indicators of nephrotoxicity. On the other hand, statistically significantly increased NAG activity observed in the gentamicin-receiving group points to more severe gentamicin-provoked injuries of proximal tubules. Keywords: alanine aminopeptidase (AAP), gamma-glutamyl transferase (GGT), N-acetyl-beta-D-glucosaminidase (NAG), urine, gentamicin, nephrotoxicity Address for correspondence: @ivko Sani~anin Faculty of Medicine University of Banjaluka, Republic of Srpska Kratak sadr`aj: Radi utvr ivanja nefrotoksi~nosti aminoglikozidnog antibiotika gentamicina, odre ivana je aktivnost enzima dominantno lociranih u proksimalnim tubulama: alanin aminopeptidaze (AAP), gama-glutamiltransferaze (GGT) i N-acetil-beta-D-glukozaminidaze (NAG), u uzorcima 12-~asovnog urina u 30 ispitanika kojima je, zbog gram-negativnih infekcija, intravenski apliciran gentamicin. Aktivnost istih enzima odre ivana je i u 12-~asovnom urinu 30 ispitanika kontrolne grupe. Polnu strukturu grupa ~inili su ispitanici oba pola, starosti od 3 do 10 godina. Predtretman, sa obe grupe i bez apliciranja gentamicina, vo en je 5 dana, a tretman u periodu od 10 dana, pri ~emu su ispitanici eksperimentalne grupe primali jednokratno gentamicin u dozama od 2,5 mg/kg tjelesne mase dnevno. Zna~ajne razlike u aktivnostima AAP i GGT, u U/mmol kreatinina, utvr ene su izme u eksperimentalne i kontrolne grupe drugog dana (p<0,05), i u aktivnostima NAG osmog dana (p<0,01) sprovo enja terapije. Mo`e se zaklju~iti da desetodnevni tretman gentamicinom, ~ak i sa normalnim dozama, uslovljava nefrotoksi~ne efekte. Pri tom su statisti- ~ki zna~ajno povi{ene vrijednosti AAP i GGT ranih i ekstremno osjetljivih indikatora nefrotoksi~nosti, dok je statisti~ki zna~ajno povi{enje aktivnosti NAG dijagnosti~ki znak gentamicinom izazvanih te`ih o{te}enja proksimalnih tubula. Klju~ne rije~i: alanin aminopeptidaza (AAP), gama-glutamil transferaza (GGT), N-acetil-beta-D-glukozaminidaza (NAG), urin, gentamicin, nefrotoksi~nost Introduction Aminoglycoside antibiotics play a leading role in the therapy of different Gram-negative infections during which nephrotoxic complications were recorded in 10 15% of cases (1). Secondary nephrotoxicity of gentamicin was shown to be related to the action of free oxygen radicals (2), and it is accompanied by

JMB 2007; 26 (1) 47 increased activities of AAP (EC 3.4.11.2), GGT (EC 2.3.2.2) and NAG (EC 3.2.1.30) in urine, all these enzymes being dominantly localized in the proximal tubules (3). Numerous authors clearly demonstrated the nephrotoxic effects of high gentamicin doses applied to experimental animals by the determination of AAP, GGT and NAG activites in urine (4 10). However, the results of clinical studies performed on patients receiving a standard gentamicin dose of 2.5 mg/kg b.w. for 10 days, aimed at the examination of whether the changes in activity of the above-mentioned enzymes in urine could serve as reliable markers of gentamicin-related early injuries of proximal tubules, were somewhat contradictory (11 13). This prompted us to examine the activity of AAP, GGT and NAG in urine samples of patients treated for 10 days with a standard gentamicin dose of 2.5 mg/kg b.w. and to find out whether these enzymes could serve as markers of early proximal tubule injuries. Materials and Methods The examinations included sixty 3 10 years old children of both sexes, patients of the Pediatric Clinic of the Clinical Centre in Banjaluka. Thirty children were treated with a single i.v. injection of gentamicin, in the dose of 2.5 mg/kg b.w./day during 10 consecutive days, against Gram-negative bacterial infections. A group of 30 age- and sex structure-matched children without health problems with the urogenital tract served as controls. Morning 12-h urine was collected and kept at 25 C till the analyses of enzyme activities. Urine collection started 5 days before the onset of gentamicin treatment. The data on the age, sex and state of health of the patients were obtained by a questionnaire on the first day of the collection of urine samples. In order to separate the enzymes, urine samples were subjected to gel filtration (14). The activities of AAP (15), GGT (16, 17) and NAG (18), as well as creatinine concentrations (19), were determined by photometry. Enzyme activities were expressed as U/mmol creatinine. The results were analyzed by standard statistical methods and expressed as means ±S.D. Significance of the differences between the groups was evaluated by Student s t-test. Statistical significance was accepted at p<0.05. Figure 1 Enzymatic activity of AAP in urine of children receiving a single gentamicin injection in the dose of 2.5 mg/kg b.w./day i.v., 4 and 2 days before gentamicin application and on days 2, 4, 6, 8 and 10 of therapy, and in urine of the corresponding controls. Results are expressed as means ±S.D. GGT enzymuria (units/mmol creatinine) 8 6 4 2 control group experimental group 0 5 0 5 10 Days Results Mean values of AAP, GGT and NAG activities, expressed in U/mmol creatinine, are depicted in Figures 1, 2 and 3, respectively. During the 5-day pretreatment period, variations in the activity of exami- Figure 2 Enzymatic activity of GGT in urine of children treated with a single gentamicin injection in the dose of 2.5 mg/kg b.w./day by i.v. route, 4 and 2 days before the onset of gentamicin therapy and on days 2, 4, 6, 8 and 10 of therapy, and in urine of the corresponding controls. Results are expressed as means ±S.D.

48 Davidovi} at al.: Proximal tubule enzymes in patients treated with gentamicin increase in the activity of this enzyme was recorded on day 8 of the treatment and the mean values were significantly higher in the gentamicin-treated group in comparison with the controls ( x = 0.85 ± 0.19 vs. x = 0.35 ± 0.13; p<0.01). The level of statistical significance between the groups remained constant during the last two days of gentamicin therapy. Figure 3 Enzymatic activity of NAG in urine of children receiving i.v. a single gentamicin injection in the dose of 2.5 mg/kg b.w./day, 4 and 2 days before gentamicin treatment and on days 2, 4, 6, 8 and 10 of therapy, and in urine of the corresponding controls. Results are expressed as means ±S.D. ned enzymes of 4.0% (AAP), 4.8% (GGT) and 8.3% (NAG), were negligible. Statistically significant increase of AAP activity ( x = 0.60 ± 0.15), expressed as mean value ±S.D. in relation to that of the control group ( x = 0.37 ± 0.07; p < 0.05) was recorded already on the second day after the onset of the therapy (Figure 1). During the following days of gentamicin treatment, increased AAP activity was observed, but the level of statistical significance of the differences between the gentamicin-treated group and the control one remained roughly the same. The activity of GGT was also significantly increased in the gentamicin-treated group of patients in comparison with the control group ( x = 6.0 ± 1.3 vs. x = 3.9 ± 0.8; p<0.05) on the second day of the therapy, and, similar to AAP, the level of statistical significance of the differences between the groups was roughly the same till the end of the antibiotic application (Figure 2). From the data graphically presented in Figure 3, it can be seen that the activity of NAG was almost unchanged in the gentamicin-treated group in relation to controls during the first seven days of therapy. The Discussion In the present study, the possible nephrotoxicity of gentamicin given in a single i.v. dose of 2.5 mg/kg/ /day to 3 10 years old children with Gramnegative infections was examined. The study was based on the results of Bennet (20), who reported that aminoglycoside nephrotoxicity is characterized by decreased glomerular filtration and necrosis of proximal tubules accompanied by increased activities of the enzymes localized within the proximal tubules which are excreted in urine. The examinations included 3 10 years old children, because, as shown previously, the excretion of enzymes from proximal tubules in infants is unstable and relatively lower values were obtained for the activity of the characteristic enzymes in urine, when compared to older children (21). The gentamicin-treated group consisted of children with Gram-negative infections, 40% of which suffered from urinary tract infections and 60% from pyelonephritis. Our results confirmed the hypothesis that even if applied in normal doses, gentamicin expresses nephrotoxic effects at the cellular level, resulting in increased activities of several proximal tubule enzymes. The increase of brush border enzyme activities, i.e. AAP and GGT, was observed rather early, already on day 2 of the gentamicin therapy, while that of the NAG was recorded much later, on day 8 of this antibiotic application (Figures 1 3). This is in disaccord with the results of Ahijad and Garcia (22) who reported the appearance of the first nephrotoxic gentamicin-induced symptoms on day 7 of gentamicin therapy. After the first elevation of AAP and GGT activity observed in the present study, the level of significance of the differences between the gentamicin-treated group of children and the corresponding control remained roughly the same. This means that nephrotoxicity depends on individual gentamicin dose and not on the duration of therapy. Opposite to that, our results showed increased NAG activity close to the end of therapy, suggesting that it was more dependent on the duration of gentamicin treatment than on the dose applied. Similar to the data of Kos et al (13), the results presented here showed that increased activity of proximal tubule enzymes in urine was not accompanied by clinical signs of kidney injuries. Faster response of AAP and GGT during gentamicin application in comparison to that of NAG could be ascribed to the appearance of pathohistological changes of kidney tubule organelles at subcellular level at

JMB 2007; 26 (1) 49 the different time points of the therapy. It is also possible that different mechanisms are involved in the control of these enzyme activities. It is quite believable that two independent mechanisms play a role in gentamicin-related nephrotoxicity, i.e. that brush border cells of the proximal tubule epithelium are much more sensitive and respond much earlier to single daily gentamicin doses than the lysosomes of proximal tubule cells. Because of that, increased activities of AAP and GGT could be interpreted as the sign of less severe injury of proximal tubule cells, and these two enzymes could be taken as early and very sensitive indicators of gentamicin nephrotoxicity. Damages of lysosomes in proximal tubule cells result from the cumulative action of gentamicin, and this was the reason for the relatively late increase of NAG activity which can be considered as an indicator of more severe injuries of proximal tubule cells. From the results obtained throughout the present study, it can be concluded that even normal gentamicin doses express nephrotoxic effects followed by elevated enzymatic activities of AAT, GGT and NAG, i.e. enzymes dominantly localized within the proximal tubules. Since both AAT and GGT responded to gentamicin treatment already on the 2nd day of the therapy, they are obviously very sensitive and reliable indicators of the nephrotoxicity of this aminoglycoside antibiotic. As shown here, NAG activity depends more on the duration of therapy than on the individual gentamicin doses applied, and increased activity of this enzyme indicates more serious damages of proximal tubule cells. References 1. Musso CG. Aminoglycoside and nephropathy. Electron J Biomed 2004; 2: 2 4. 2. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Di Paola R, Britti D, et al. A role for superoxide in gentamicin-mediated nephropathy in rats. Eur J Pharmacol 2002; 450: 76 6. 3. Trajtnar F. Urinary enzymes as indicators of aminoglycoside nephrotoxicity. Folia Pharm Univ Carol 1995; 19: 91 9. 4. Whiting PH, Brown J. The relationship between enzymuria and kidney enzyme activities in experimental gentamicin nephrotoxicity. Ren Fail 1996; 18 (6): 899 909. 5. Van der Harst MR, Bull S, Laffont CM, Klein WR. Gentamicin nephrotoxicity a comparison of in vitro findings with in vivo experiments in equines. Vet Res Commun 2005; 29 (3): 247 61. 6. Lenz FM, Bright J, Knight R, Westwood FR, Davies D, Major H, et al. Metabonomics with 1-H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers 2005; 10 (2 3): 173 87. 7. Rivers BJ, Walter PA, O Brien TD, King VL, Polzin DJ. Evaluation of urine gamma-glutamyl transpeptidase- -to-creatinine ratio as a diagnostic tool in an experimental model of aminoglycoside-induced acute renal failure in the dog. J Anim Hosp Assoc 1996; 32(4): 323 36. 8. Fauconneau B, Favreliere S, Pariat C, Genevrier A, Courtois P, Piriou A, et al. Nephrotoxicity of gentamicin and vancomycin given alone and in combination as determined by enzymuria and cortical antibiotic levels in rats. Ren Fail 1997; 19 (1): 15 22. 9. Rossier Y, Divers TJ, Sweeney RW. Variations in urinary gamma-glutamyltransferase/urinary creatinine ratio in horses with or without pleuropneumonia treated with gentamicin. Equine Vet J 1995; 27 (3): 217 20. 10. Grauer GF, Greco DS, Behrend EN, Mani I, Fettman MJ, Allen TA. Estimation of quantitative enzymuria in dogs with gentamicin-induced nephrotoxicosis using urine enzyme/creatinine ratios from spot urine samples. J Vet Intern Med 1995; 9 (5): 324 7. 11. Kavukcu S, Soylu A, Turkmen M. The clinical value of urinary N-acetyl-beta-D-glucosaminidase levels in childhood age group. Acta Med Okayama 2002; 56 (1): 7 11. 12. Wiland P, Szechcinski J. Proximal tubule damage in patients treated with gentamicin or amikacin. Pol J Pharmacol 2003; 55 (4): 631 7. 13. Kos M, Jazwinska-Taranawska E, Hurkacz M, Orzechowska-Juzwenko K, Pilecki W, Klempons J. The influence of locally implanted high doses of gentamicin on hearing and renal function of newborns treated for acute hematogenous osteomyelitis. Int J Clin Pharmacol Ther 2003; 41 (7): 281 6. 14. Werner M, Maruhn D, Atoba M. Use of gel filtration in the assay of urinary enzymes. J Chromatog 1969; 40: 254 63. 15. Jung K, Scholz D. An optimized assay of alanine aminopeptidase activity in urine. Clin Chem 1980, 26/9: 1251 4. 16. Persijn JP, Van der Slik W. A new method for the determination of gamma-glutamyltransferase in serum. J Clin Chem Clin Biochem 1976; 14 (9): 421 7. 17. Szasz G. A kinetic colorimetric method for determination of g-glutamyltranspeptidase in serum. Z Klin Chem Klin Biochem 1974; 12 (5): 228 32. 18. Maksime J, Saito E, Obuchi M, Kanayama M, Harakawa K, Yosida U. Improved kinetic rate assay of urinary N- acetyl-beta-d-glucosaminidase with 2-chloro-4-nitrophenyl-N-acetyl-beta-D-glucosaminidase as substrate. Clin Chem 1990; 36/2: 319 22.

50 Davidovi} at al.: Proximal tubule enzymes in patients treated with gentamicin 19. Bartels H, Böhmer M. Eine Mikromethode zur Kreatininbestimmung. Clin Chim Acta 1971; 32 (1): 81 5. 20. Bonnett WM. Comparison of cyclosporine nephrotoxicity with aminoglycoside nephrotoxicity. Clin Nephrol 1986; 25 (Suppl. 1): 126 9. 21. Heimann G. Renal toxicity of aminoglycosides in the neonatal period. Pediatr Oharmacol 1983; 3 (3 4): 254 7. 22. Alijado FJ, Garcia S. Insuficiencia renal aguda por nefrotoxicos. In Liano F, Pascual J (eds). Insuficiencia renal aguda. Barcelona, Masson 2000: 143 6. Received: August 25, 2006 Accepted: November 10, 2006